Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants

Drug Safety

Volumn 26, Issue 5, 2003, Pages 303-335

  Sivin, Irving ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; LIPID; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SINOPLANT 1; SINOPLANT 2; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANXIETY DISORDER; ARTHROPATHY; BORDERLINE HYPERTENSION; CANCER STATISTICS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DEVICE REMOVAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RELEASE; DRUG SAFETY; ECTOPIC PREGNANCY; FEMALE; FOOD AND DRUG ADMINISTRATION; GALLBLADDER DISEASE; HEADACHE; HEALTH HAZARD; HEMOSTASIS; HUMAN; HYPERTENSION; IMPLANT; IMPLANT REMOVAL; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALAISE; MENSTRUATION DISORDER; MORTALITY; NERVOUSNESS; NEUROPATHY; OBESITY; OVARY CYST; PATIENT SATISFACTION; PELVIC INFLAMMATORY DISEASE; POPULATION RESEARCH; PREGNANCY COMPLICATION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; STATISTICS; THROMBOCYTOPENIA; VERTIGO; VISUAL DISORDER;

CONTRACEPTIVE AGENTS, FEMALE; DRUG IMPLANTS; FEMALE; HUMANS; LEVONORGESTREL; PROGESTERONE CONGENERS; RISK;

EID: 0037256027     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326050-00002     Document Type: Review

References (162)

1. Harrison PF, Rosenfield A. Effect of media coverage and litigation on Norplant® use. In: Harrison PF, Rosenfield A, editors. Contraceptive research, introduction and use: lessons from Norplant®. Washington, DC: National Academy Press, 1998: 21-2
2. Kalmuss D, Davidson AR. Utilization data: Norplant® discontinuation among low-income women. In: Harrison PF, Rosenfield A, editors. Contraceptive research, introduction and use; lessons from Norplant®. Washington, DC: National Academy Press, 1998: 79-82
3. Meirik O. Implantable contraceptives for women. Contraception 2002; 65 (1): 1-2
4. Meirik O, Farley TM, Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet Gynecol 2001; 97 (4): 539-47
5. Sivin I. International experience with Norplant® and Norplant®-2 contraceptives. Stud Fam Plann 1988; 19 (2): 81-94
6. Sivin I. Norplant® contraceptive implants. In: Shoupe D, Haseltine FP, editors. Contraception. New York (NY): Springer-Verlag, 1993: 131-43
7. Fraser IS, Tiitinen A, Affandi B, et al. Norplant® consensus statement and background review. Contraception 1998; 57 (1): 1-9
8. Coukell AJ, Balfour JA. Levonorgestrel subdermal implants: a review of contraceptive efficacy and acceptability. Drugs 1998; 55 (6): 861-87
9. Darney PD. Implantable contraception. Eur J Contracept Reprod Health Care 2000; 5 Suppl. 2: 2-11
10. Meckstroth KR, Darney PD. Implantable contraception. Obstet Gynecol Clin North Am 2000; 27 (4): 781-815
11. Meckstroth KR, Darney PD. Implant contraception. Semin Reprod Med 2001; 19 (4): 339-54
12. French RS, Cowan FM, Mansour DJ, et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000; 4 (7): i-vi, 1-107
13. Sivin I, Lahteenmaki P, Ranta S, et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception 1997; 55 (2): 81-5
14. Olsson SE, Odlind V, Johansson ED, et al. Plasma levels of levonorgestrel and free levonorgestrel index in women using Norplant® implants or two covered rods (Norplant®-2). Contraception 1987; 35 (3): 215-28
15. Fan H, Han L. A multicenter clinical comparative study of domestically produced implant contraceptives no. I and no. II with Norplant®. J Reprod Med 1999; 8 Suppl. 1: 47-53
16. Population Council, Jadelle,® New Drug Approval (NDA) 20-544, with supplements, 2002
17. Population Council, Norplant® New Drug Approval (NDA) 19-897, with supplements, 2002
18. Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle® contraceptive implants. Contraception 2001; 64 (1): 43-9
19. Du M, Shao Q, Zhou X. Serum levels of levonorgestrel during long-term use of Norplant® [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 1999; 34 (6): 363-5
20. Sivin I, Campodonico I, Kiriwat O, et al. The performance of levonorgestrel rod and Norplant® contraceptive implants: a 5-year randomized study. Hum Reprod 1998; 13 (12): 3371-8
21. Sivin I, Viegas O, Campodonico I, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant® implants as controls. Contraception 1997; 55 (2): 73-80
22. Sivin I, Alvarez F, Mishell Jr DR, et al. Contraception with two levonorgestrel rod implants: a 5-year study in the United States and Dominican Republic. Contraception 1998; 58 (5): 275-82
23. Sivin I, Nash H, Waldman S. Jadelle® levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience. New York: Population Council, 2002: 1-64
24. Sivin I, Mishell Jr DR, Diaz S, et al. Prolonged effectiveness of Norplant® capsule implants: a 7-year study. Contraception 2000; 61 (3): 187-94
25. Sivin I, Mishell Jr DR, Darney P, et al. Levonorgestrel capsule implants in the United States: a 5-year study. Obstet Gynecol 1998; 92 (3): 337-44
26. Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174 (4): 1161-8
27. Affandi B, Hoesni HM, Barus RP, et al. A multicentered phase III comparative study between single-implant containing 3 ketodesogestrel (Implanon®) and implants containing levonorgestrel (Norplant®): I. efficacy and, acceptability and safety (three year results). Med J Indonesia 1999; 8 (1): 49-55
28. Zheng SR, Zheng HM, Qian SZ, et al. A randomized multicenter study comparing the efficacy and bleeding pattern of asingle-rod (Implanon) and a six-capsule (Norplant®) hormonal contraceptive implant. Contraception 1999; 60 (1): 1-8
29. Wang SL, Wu SC, Xin XM, et al. Three years' experience with levonorgestrel-releasing intrauterine device and Norplant®-2 implants: a randomized comparative study. Adv Contracept 1992; 8 (2): 105-14
30. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon: an overview of the data. Contraception 1998 Dec; 58 (6 Suppl.): 91S-7S
31. Croxatto HB, Urbansek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 1999 Apr; 14 (4): 976-81
32. Han L. A 5-year multicenre comparative study of domestically produced implant contraceptives no. I and no. II with Norplant®. Presentation at WHO, 2001 May
33. Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 2002; 65: 29-37
34. Gao J, Wang SL, Wu SC, et al. Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant®-2 implants in China. Contraception 1990; 41 (5): 485-94
35. Gu SJ, Du MK, Zhang LD, et al. A 5-year evaluation of NORPLANT® contraceptive implants in China. Obstet Gynecol 1994; 83 (5 Pt 1): 673-8
36. Gu S, Sivin I, Du M, et al. Effectiveness of Norplant® implants through seven years: a large-scale study in China. Contraception 1995; 52 (2): 99-103
37. Gu S, Du M, Zhang L, et al. A five-year evaluation of NORPLANT® II implants in China. Contraception 1994; 50 (1): 27-34
38. Meirik O, Farley TMM, Diaz S, et al. Post-marketing surveillance of Norplant® contraceptive implants: I. contraceptive efficacy and reproductive health. Contraception 2001; 63 (4): 167-86
39. Fu H, Darroch JE, Haas T, et al. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31 (2): 56-63
40. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31 (2): 64-72, 93
41. Fisher AA, Prihartono J, Tuladhar J, et al. An assessment of Norplant® removal in Indonesia. Stud Fam Plann 1997; 28 (4): 308-16
42. Sivin I. Fertility decline and contraceptive use in the International Postpartum family Planning Program. Stud Fam Plann 1971; 2: 248-56
43. Meirik O, Farley TMM, Collins J, et al. Post-marketing surveillance of Norplant® contraceptive implants: II. non-reproductive health. Contraception 2001; 63 (4): 187-209
44. Vessey M, Doll R, Peto R, et al. A long term follow-up study of women using different methods of contraception - an interim report. J Biosoc Sci 1976; 8 (4): 373-427
45. Ramcharan S, Pellegrin FA, Ray RM, et al. The Walnut Creek Contraceptive Drug Study: a prospective study of the side effects of oral contraceptives. J Reprod Med 1980; 25: 346-72
46. Royal College of General Practitioners. Oral contraceptives and Health. London: Pitman Medical, 1974
47. Curtis KM. Safety of implantable contraceptives for women: data from observational studies. Contraception 2002; 645: 85-96
48. Wysowski DK, Green L. Serious adverse events in Norplant® users reported to the Food and Drug Administrations's MedWatch spontaneous reporting system. Obstet Gynecol 1995; 85: 538-542
49. Sivin I. Serious adverse events in Norplant® users reported to the Food and Drug Administration's MedWatch spontaneous reporting system. Obstet Gynecol 1995 Aug; 86 (2): 318-20
50. Petitti DB, Siscovick DS, Sidney S, et al. Norplant® implants and cardiovascular disease. Contraception 1998; 57: 361-2
51. World Health Organization. Collaborative study of cardiovascular disease and steroid hormone contraception: cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 1998; 57: 315-24
52. Poulter NR, Chang CL, Farley TM, et al. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1999; 354 (9175): 301-2
53. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation: Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999; 318 (7175): 13-8
54. Sivin I. Clinical effects of NORPLANT® subdermal implants for contraception. In: Mishell Jr DR, editor. Long-acting steroid contraception. New York: Raven Press, 1983: 89-116
55. Liu X, Mao J, Chen X, et al. The safety of Sino-implant-3-year clinical observation. Shengzhi Yu Biyun 1999; 10 (4): 234-41
56. Alder JB, Fraunfelder FT, Edwards R. Levonorgestrel implants and intracranial hypertension. N Engl J Med 1995 Jun 22; 332 (25): 1720-1
57. Thijs C, Knipschild P. Oral contraceptives and the risk of gallbladder disease: a meta-analysis. Am J Public Health 1993; 83: 1113-20
58. Farley TMM, Rosenberg MJ, Rowe, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785-8
59. Wagner K, Berenson A. Norplant® associated-major depression and panic disorder. J Clin Psych 1994; 55: 478-80
60. Wagner K. Major depression and anxiety disorders associated with Norplant®. J Clin Psych 1996; 57: 152-7
61. Stevens-Simon C, Kelly L, Wallis J. The timing of Norplant® insertion and postpartum depression in teenagers. J Adolesc Health 2000; 26 (6): 408-13
62. Westhoff C, Truman C, Kalmuss D, et al. Depressive symptoms and Norplant® contraceptive implants. Contraception 1998; 57 (4): 241-5
63. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective tissue disease. N Engl J Med 2000; 342: 781-90
64. Dorflinger LJ. Metabolic effects of steroids used in implantable contraceptives for women. Contraception 2002; 65: 47-62
65. Harper MA, Meis PJ, Steele L. A prospective study of insulin sensitivity and glucose metabolism in women using a continuous subdermal levonorgestrel implant system. J Soc Gynecol Investig 1997; 4 (2): 86-9
66. Koopersmith TB, Lobo RA. Insulin sensitivity is unaltered by the use of the Norplant® subdermal implant contraceptive. Contraception 1995; 51 (3): 197-200
67. Singh K, Viegas OA, Loke DF, et al. Effect of Norplant® implants on liver, lipid and carbohydrate metabolism. Contraception 1992 Feb; 45 (2): 141-53
68. Singh K, Viegas OA, Loke D, et al. Effect of Norplant® 2 rods on liver, lipid and carbohydrate metabolism. Contraception 1992; 45 (5): 463-72
69. Konje JC, Odukoya OA, Otolorin EO, et al. Carbohydrate metabolism before and after Norplant® removal. Contraception 1992; 46: 61-9
70. Konje JC, Otolorin EO, Ladipo OA. The effect of continuous subdermal levonorgestrel (Norplant®) on carbohydrate metabolism. Am J Obstet Gynecol 1992; 166 (1 Pt 1): 15-9
71. Konje JC, Otolorin EO, Ladipo OA. Changes in carbohydrate metabolism during 30 months on Norplant®. Contraception 1991; 44: 163-72
72. Lithell H, Weiner E, Vessby B, et al. Effects of continuous levonorgestrel treatment (subcutaneous capsules) on the lipoprotein and carbohydrate metabolism in fertile women. Ups J Med Sci 1983; 88 (2): 103-8
73. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant® depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 2000 Feb; 26 (1): 17-26
74. United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank (WB), Special Programme of Research development and Research Training in Human Reproduction, Task Force on long-acting systemic agents for fertility regulation. Study of the effects of the implantable contraceptive Norplant® on lipid and lipoprotein metabolism. Contraception 1999; 59 (1): 31-45
75. Rabe T, Thuro HC, Goebel K, et al. Lipid metabolism in Norplant®-2 users: a two-year follow-up study. Total cholesterol, triglycerides, lipoproteins and apolipoproteins. Contraception 1992; 45 (1): 21-37
76. Singh K, Ratnam SS. A study on the effects of Norplant® implantable contraceptive on lipid, lipoprotein, and apolipoprotein metabolism in Singaporean women. Contraception 1997; 56 (2): 77-83
77. Anwar M, Soejono SK, Maruo T, et al. Comparative assessment of the effects of subdermal levonorgestrel implant systemand long acting progestogen injection method on lipid metabolism. Asia Oceania J Obstet Gynaecol 1994; 20 (1): 53-8
78. Otubu JA, Towobola OA, Aisien AO, et al. Effects of Norplant® contraceptive subdermal implants on serum lipids and lipoproteins. Contraception 1993; 47 (2): 149-59
79. Affandi B, Suherman SK, Djajalelana, et al. Serum lipids in Norplant® implants users: a cross-sectional study. Contraception 1987; 36 (4): 429-34
80. Holma P, Robertson DN. Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel. Contraception 1985; 32 (2): 163-71
81. Shaaban MM, Elwan SI, Abdalla SA, et al. Effect of subdermal levonorgestrel contraceptive implants, Norplant® on serum lipids. Contraception 1984; 30 (5): 413-9
82. Roy S, Mishell Jr DR, Robertson DN, et al. Long-term reversible contraception with levonorgestrel-releasing Silastic rods. Am J Obstet Gynecol 1984; 148 (7): 1006-13
83. Yang P, Wu X, Yang Q, et al. The effects of Sino-implant containing LNG on lipoprotein metabolism and changes in blood HDL2-C levels. Shengzhi Yu Biyun 1999; 10 (2): 84-90
84. Egberg N, van Beek A, Gunnervik C, et al. Effects on the hemostatic system and liver function in relation to Implanon and Norplant® a prospective randomized clinical trial. Contraception 1998; 58 (2): 93-8
85. Viegas OA, Koh SC, Ratnam SS. The effects of reformulated 2-rod Norplant® implant on hemostasis after three years. Contraception 1996; 54 (4): 219-28
86. Singh K, Viegas OA, Koh SL, et al. Effect of Norplant®-2 rods on haemostatic function. Contraception 1992; 46 (1): 71-81
87. Singh K, Viegas OA, Koh SC, et al. Effect of long-term use of Norplant® implants on haemostatic function. Contraception 1992; 45 (3): 203-19
88. Singh K, Viegas OA, Ratnam SS. A three-year evaluation of hemostatic function in Singaporean Norplant®-2 rod acceptors. Adv Contracept 1990; 6 (2): 81-9
89. Singh K, Viegas OA, Ratnam SS. A three-year evaluation of hemostatic function in Singaporean Norplant® acceptors. Adv Contracept 1990; 6 (1): 23-32
90. Singh K, Viegas OA, Koh S, et al. The effects of Norplant®-2 rods on clinical chemistry in Singaporean acceptors after 1 year of use: haemostatic changes. Contraception 1988; 38 (4): 441-51
91. Gu SJ, Du MG, Yuan DY, et al. A two-year study of acceptability, side effects, and effectiveness of Norplant® and Norplant®-2 implants in the People's Republic of China. Contraception 1988; 38 (6): 641-57
92. Du MK, Zheng HM, Chen HC, et al. Study of Norplant® implants in Shanghai: three-year experience. Int J Gynecol Obstet 1990; 33: 45-57
93. Fraser JL, Millenson M, Malynn ER, et al. Possible association between the Norplant® contraceptive system and thrombotic thrombocytopenic purpura. Obstet Gynecol 1996; 87 (5 Pt 2): 860-3
94. Shaaban MM, Elwan SI, el-Sharkawy MM, et al. Effect of subdermal levonorgestrel contraceptive implants, Norplant®, on liver functions. Contraception 1984; 30: 407-12
95. McCann MF, Potter LS. Progestin-only contraception; a comprehensive review. Contraception 1994; 50 Suppl. 1: S1-195
96. Cromer BA. Effects of hormonal contraceptives on bone mineral density. Drug Saf 1999; 20 (3): 213-22
97. Cromer BA, Berg-Kelly KS, Van Groningen JP, et al. Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant®) use in adolescents among clinicians in Northern Europe and the United States. J Adolesc Health 1998; 23 (2): 74-80
98. Cromer BA, Smith RD, Blair JM, et al. A prospective study of adolescents who choose among levonorgestrel implant (Norplant®), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 1994; 94 (5): 687-94
99. Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant®) or oral contraceptives. J Pediatr 1996; 129 (5): 671-6
100. Naessen T, Olsson S-E, Gudmundson J. Differential effect on bone density of progestogen: only methods for contraception in premenopausal women. Contraception 1995; 52: 35-9
101. Di X, Li Y, Zhang C, et al. Effects of Levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. Contraception 1999; 60 (3): 161-6
102. Taneepanichskul S, Intaraprasert S, Theppisai U, et al. Bone mineral density during long-term treatment with Norplant® implants and depot medroxyprogesterone acetate: a crosssectional study of Thai women. Contraception 1997; 56 (3): 153-5
103. Petitti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000; 95: 736-44
104. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen only contraceptives and bone mineral density. BJOG 2001; 108 (12): 1214-21
105. Diaz S, Reyes MV, Zepeda A, et al. Norplant® implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum Reprod 1999; 14 (10): 2499-505
106. Brache V, Faundes A, Alvarez F, et al. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65: 63-74
107. Mitra SN, Ali MN, Islam S, et al. The Bangladesh demographic and health survey, 1993-1994. Calverton (MD): Macro International Inc. 1994
108. Li HQ, Goldberg JM, Go H. A 4-year follow-up study of women with Norplant®-2 contraceptive implants. Contraception 2001; 64: 301-3
109. Affandi B, Hoesni HM, Barus RP, et al. A multicentered phase III comparative study between single implant containing 3-ketodesogestrel (Implanon®) and implants containing levonorgestrel (Norplant®): II. vaginal bleeding patterns. Med J Indonesia 1999; 8 (1): 56-64
110. Biswas A, Leong WP, Ratnam SS, et al. Menstrual bleeding patterns in Norplant®-2 implant users. Contraception 1996; 54 (2): 91-5
111. Meng F, Fan H, Han L. Vaginal bleeding patterns and the regularity in use of Norplant® [in Chinese]. Zhonghua Yi Xue Za Zhi 1996 May; 76 (5): 331-4
112. Meng F, Gu S. Menstrual bleeding patterns in Chinese women using the Norplant® subdermal implant. Hum Reprod 1996; 11 Suppl. 2: 14-9
113. Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills): an Indian experience. An ICMR Task Force Study. Indian Council of Medical Research. Contraception 1995; 51 (3): 155-65
114. Cheng L, Zhu H, Wang A, et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000; 15 (9): 1969-72
115. Nutley T, Dunson TR. Treatment of bleeding problems associated with progestin-only contraceptives: survey results. Adv Contracept 1997; 13 (4): 419-28
116. Alvarez-Sanchez F, Brache V, Thevenin F, et al. Hormonal treatment for bleeding irregularities in Norplant® implant users. Am J Obstet Gynecol 1996; 174 (3): 919-22
117. Diaz S, Croxatto HB, Pavez M, et al. Clinical assessment of treatments for prolonged bleeding in users of Norplant® implants. Contraception 1990; 42 (1): 97-109
118. Fraser IS, Weisberg E, Minehan E, et al. A detailed analysis of menstrual blood loss in women using Norplant® and Nestorone progestogen-only contraceptive implants or vaginal rings. Contraception 2000; 61 (4): 241-51
119. Han L, Fan H, Gong Q, et al. Effects of three types of long acting contraceptive implants on menstrual blood loss in 89 women. Shengzhi Yu Biyun 1999; 10 (2): 91-7
120. Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, et al. Effects of contraceptives on hemoglobin and ferritin. Contraception 1998; 58 (5): 262-73
121. Nilsson CG, Holma P. Menstrual blood loss with contraceptive subdermal levonorgestrel implants. Fertil Steril 1981; 35 (3): 304-6
122. Frank ML, Poindexter III AN, Cornin LM, et al. One-year experience with subdermal contraceptive implants in the United States. Contraception 1993; 48 (3): 229-43
123. Crosby UD, Schwarz BE, Gluck KL, et al. A preliminary report of Norplant® implant insertions in a large urban family planning program. Contraception 1993; 48 (4): 359-66
124. Berenson AB, Wiemann CM. Patient satisfaction and side effects with levonorgestrel implant (Norplant®) use in adolescents 18 years of age or younger. Pediatrics 1993; 92 (2): 257-60
125. Klavon SL, Grubb GS. Insertion site complications during the first year of NORPLANT® use. Contraception 1990; 41 (1): 27-37
126. Nuovo J, Sweha A. Keloid formation from levonorgestrel implant (Norplant® System) insertion. J Am Board Fam Pract 1994; 7 (2): 152-4
127. Sarma SP, Hatcher RP. Neurovascular injury during removal of levonorgestrel implants. Am J Obstet Gynecol 1995; 172 (1 Pt 1): 120-1
128. Sarma SP, Silverstein M, Lewis C. Removal of a Norplant® implant located near a major nerve using interventional radiology-digital subtraction fluoroscopy. Contraception 1998; 58 (6): 387-9
129. Smith JM, Conwit RA, Blumenthal PD. Ulnar nerve injury associated with removal of Norplant® implants. Contraception 1998; 57 (2): 99-101
130. Hueston WJ, Locke KT. Norplant® neuropathy: peripheral neurologic symptoms associated with subdermal contraceptive implants. J Fam Pract 1995; 40 (2): 184-6
131. Marin R, McMillian D. Ulnar neuropathy associated with subdermal contraceptive implant. South Med J 1998; 91 (9): 875-8
132. Creinin MD, Klaisle CM. Removal of levonorgestrel capsules from the biceps muscle. Int J Gynaecol Obstet 1995; 50 (2): 189-91
133. Sarma SP, Wamsher JG, Whitlock SW. Removal of deeply inserted, nonpalpable levonorgestrel (Norplant® implants. Contraception 1996; 53 (3): 159-61
134. Crist T, Barnes MR, Whitehurst WC. Difficulty finding and removing a Norplant® system capsule [letter]. N C Med J 1994; 55 (2): 76
135. Weiner HM, DiMarcangelo MT, Heim JA, et al. Use of computed tomography guidance and mammographic hook wires to remove displaced, embedded contraceptive rods. J Am Osteopath Assoc 1996; 96 (7): 422-3
136. Dunson TR, Amatya RN, Krueger SL. Complications and risk factors associated with the removal of Norplant® implants. Obstet Gynecol 1995; 85 (4): 543-8
137. Wehrle KE. The Norplant® System: easy to insert, easy to remove. Nurse Pract 1994; 19 (4): 47-54
138. Shaaban MM, Odlind V, Salem HT, et al. Levonorgestrel concentrations in maternal and infant serum during use of subdermal levonorgestrel contraceptive implants, Norplant® by nursing mothers. Contraception 1986; 33 (4): 357-63
139. Diaz S, Herreros C, Juez G, et al. Fertility regulation in nursing women: VII. influence of NORPLANT® levonorgestrel implants upon lactation and infant growth. Contraception 1985; 32 (1): 53-74
140. Shaaban MM, Salem HT, Abdullah KA. Influence of levonorgestrel contraceptive implants, NORPLANT®, initiated early postpartum upon lactation and infant growth. Contraception 1985; 32 (6): 623-35
141. Diaz S. Contraceptive implants and lactation. Contraception 2002; 65 (1): 39-46
142. Shaaban MM. Contraception with progestogens and progesterone during lactation. J Steroid Biochem Mol Biol 1991; 40 (4-6): 705-10
143. Taneepanichskul S, Tanprasertkul C. Use of Norplant® implants in the immediate postpartum period among asymptomatic HIV-1-positive mothers. Contraception 2001; 64 (1): 39-41
144. Taneepanichskul S, Intaraprasert S, Phuapradit W, et al. Use of Norplant® implants in asymptomatic HIV-1 infected women. Contraception 1997; 55 (4): 205-7
145. Polaneczky M, Slap G, Forke C, et al. The use of levonorgestrel implants (Norplant® for contraception in adolescent mothers. N Engl J Med 1994; 331 (18): 1201-6
146. Ricketts SA. Repeat fertility and contraceptive implant use among Medicaid recipients in Colorado. Fam Plann Perspect 1996; 28 (6): 278-80, 284
147. Blumenthal PD, Wilson LE, Remsburg RE, et al. Contraceptive outcomes among post-partum and post-abortal adolescents. Contraception 1994; 50 (5): 451-60
148. Samil RS, Kramadibrata S, Affandi B. Levonorgestrel implant contraceptive during lactation: effect on infant's growth in one-year. Presented at the Sixth Annual Meeting of the Society for the Advancement of Contraception; 1988 May 23-26; Tokyo, Japan,
149. Kalmuss D, Davidson A, Cushman L, et al. Potential barriers to the removal of Norplant® among family planning clinic patients. Am J Public Health 1998; 88 (12): 1846-50
150. Cullins VE, Remsburg RE, Blumenthal PD, et al. Comparison of adolescent and adult experiences with Norplant® levonorgestrel contraceptive implants. Obstet Gynecol 1994 Jun; 83 (6): 1026-32
151. Vekemans M, Delvigne A, Paesmans M. Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant®): a prospective study in Belgium. Contraception 1997 Nov; 56 (5): 291-9
152. Glantz S, Schaff E, Campbell-Heider N, et al. Contraceptive implant use among inner city teens. J Adolesc Health 1995; 16 (5): 389-95
153. Glantz S, Glantz JC, Campbell-Heider N, et al. Norplant® use among urban minority women in the United States. Contraception 2000; 61 (2): 83-90
154. Taneepanichskul S, Intharasakda P. Efficacy and side effects of Norplant® use in Thai women above the age of 35 years. Contraception 2001; 64 (5): 305-7
155. Ortayli N, Bulut A, Sahin T, et al. Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant® and traditional methods. Contraception 2001; 63 (6): 309-14
156. Kurunmaki H. Contraception with levonorgestrel-releasing subdermal capsules, Norplant® after pregnancy termination. Contraception 1983; 27: 473-82
157. Ashraf T, Arnold SB, Maxfield Jr M. Cost-effectiveness of levonorgestrel subdermal implants: comparison with other contraceptive methods available in the United States. J Reprod Med 1994; 39 (10): 791-8
158. Trussell J, Leveque JA, Koening JD, et al. The economic value of contraception: a comparison of 14 methods. Am J Public Health 1995; 58: 494-503
159. Westfall JM, Main DS. The contraceptive implant and the injectable: a comparison of costs. Fam Plann Perspect 1995; 27 (1): 34-6
160. Ortmeier BG, Sauer KA, Langley PC, et al. A cost-benefit analysis of four hormonal contraceptive methods. Clin Ther 1994; 16 (4): 707-13
161. Janowitz B, Kanchanasinith K, Auamkul N, et al. Introducing the contraceptive implant in Thailand: impact on method use and costs. Int Fam Plann Perspect 1994 Dec; 20 (4): 131-6
162. Hannaford P. Postmarketing surveillance study of Norplant® in developing countries. Lancet 2001; 357 (9271): 1815-6